These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11569905)

  • 1. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.
    Ahrens N; Salama A; Haas J
    J Neurol; 2001 Aug; 248(8):713-4. PubMed ID: 11569905
    [No Abstract]   [Full Text] [Related]  

  • 2. Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Dec; 19(10):632-3. PubMed ID: 17299605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil, Crohn's disease, measles?
    Altschuler EL
    Am J Gastroenterol; 2000 Feb; 95(2):550-1. PubMed ID: 10685769
    [No Abstract]   [Full Text] [Related]  

  • 4. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent.
    Katz KH; Marks JG; Helm KF
    J Am Acad Dermatol; 2000 Mar; 42(3):514-5. PubMed ID: 10688729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.
    Zhu Z; You W; Xie Z; Wang P; Liu Z; Wang C; Bi J
    J Int Med Res; 2014 Apr; 42(2):530-41. PubMed ID: 24496150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients.
    Budde K; Braun KP; Glander P; Böhler T; Hambach P; Fritsche L; Waiser J; Mai I; Neumayer HH
    Transplant Proc; 2002 Aug; 34(5):1748-50. PubMed ID: 12176561
    [No Abstract]   [Full Text] [Related]  

  • 7. Mycophenolate mofetil in multiple sclerosis.
    Frohman EM; Brannon K; Racke MK; Hawker K
    Clin Neuropharmacol; 2004; 27(2):80-3. PubMed ID: 15252268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil: a dermatologic perspective.
    Mydlarski PR
    Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From mechanisms to long-term benefits.
    Mamelok R
    Transplantation; 2005 Feb; 79(3 Suppl):S43-4. PubMed ID: 15699749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid.
    Hiemstra TF; Jones RB; Jayne DR
    Nephron Clin Pract; 2010; 116(1):c1-10. PubMed ID: 20484933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.
    Hauser RA; Malek AR; Rosen R
    Neurology; 1998 Sep; 51(3):912-3. PubMed ID: 9748061
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
    Takebe N; Cheng X; Wu S; Bauer K; Goloubeva OG; Fenton RG; Heyman M; Rapoport AP; Badros A; Shaughnessy J; Ross D; Meisenberg B; Tricot G
    Clin Cancer Res; 2004 Dec; 10(24):8301-8. PubMed ID: 15623606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
    Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
    Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pemphigus vulgaris with mycophenolate mofetil.
    Enk AH; Knop J
    Lancet; 1997 Aug; 350(9076):494. PubMed ID: 9274594
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
    Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
    Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term control of papular dermatitis ("dermal hypersensitivity reaction") with mycophenolate mofetil.
    Flugman SL
    Arch Dermatol; 2006 Nov; 142(11):1512-3. PubMed ID: 17116853
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
    Larkin G; Lightman S
    Ophthalmology; 1999 Feb; 106(2):370-4. PubMed ID: 9951492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis.
    Treiber G
    Am J Gastroenterol; 2000 Dec; 95(12):3674-5. PubMed ID: 11151935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.